WhichPepsPeptides. Without the hype.

5-Amino-1MQ

Small-molecule NNMT inhibitor

Obesityadiposity and metabolic…
Generic peptide vial illustration5-Amino-1MQ
Entity typeSmall molecule
Evidence reviewed2026-09-18
Canonical record5AMINO1MQ
Page updated2026-09-20
Evidence profilePreclinical only — positive mouse metabolic data, no human therapeutic evidence
Human evidenceNone established
Regulatory statusNo FDA/EMA approval identified
Choose your depthStart simple, then open the evidence or technical detail only if you need it.
Quick answerPlain languageEvidenceOutcomes and studiesStudiesPrimary recordsTechnicalMechanism, route and identifiers

In plain English

30-second evidence answer

What does the evidence mean in simple terms?

Most of the evidence is from laboratory and animal research. We did not identify established human treatment trials showing that 5-Amino-1MQ causes meaningful weight loss or is safe for routine human use.

Still uncertain: Whether it causes meaningful weight loss in people, dose, long-term safety, cardiovascular risk or chronic toxicity.

New to terms such as “preclinical”, “randomized” or “investigational”? Use the plain-English glossary →

What does the evidence mean in simple terms? table
What is it?Small-molecule NNMT inhibitor
Entity typeSmall molecule
Research focusObesity, adiposity and metabolic research
Human evidenceNo established therapeutic human trial evidence was identified in this review.
Regulatory statusNo FDA/EMA-approved therapeutic product identified.
Main limitationsHuman weight-loss efficacy, dose, long-term safety, cardiovascular risk or chronic toxicity.
SafetyHuman pharmacokinetics, toxicity and long-term safety are not established.
Evidence reviewed2026-09-18
i
No established therapeutic human trial evidence was identified in this review.
Outcome-level evidence

Evidence is not one score.

Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.

How to read this →

Weight/fat reduction and metabolic improvement

Preclinical evidence
Preclinical only

Context: Weight-management / metabolic interest

Finding: Positive metabolic effects are demonstrated in animal models, not people.

Uncertainty / evidence gap: No human efficacy or human therapeutic dose established.

Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.

Evidence synthesis

  • ✓Positive metabolic effects are demonstrated in animal models, not people.

Important limitations

  • !Small-molecule NNMT biology and mouse PK cannot define a human therapeutic window.

Selected study & evidence records

NNMT inhibition with 5-Amino-1MQ in diet-induced obese mice

2018 · Preclinical cell and animal study

NNMT inhibition reduced obesity-related measures in mice and altered metabolic pathways.

Study detail → Primary source ↗

5A1MQ metabolic effects in diet-induced obese mice

2024 · Preclinical animal PK/efficacy study

5A1MQ dose-dependently limited weight/fat gain and improved glucose/insulin and liver measures in mice.

Study detail → Primary source ↗

Safety and unknowns

Human pharmacokinetics, toxicity and long-term safety are not established.

Human pharmacokinetics, therapeutic window, chronic toxicity and interaction profile are not established.

Technical details

Mechanism / biologyInhibits nicotinamide N-methyltransferase (NNMT), altering methyl/nicotinamide metabolism in experimental models.
Route / formulation boundary5-Amino-1MQ is a small-molecule research compound, not a peptide.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No published human interventional dosing identified; numerical exposures in the primary literature are preclinical.
Identifiers & alternate names5 Amino 1Mq

Source depth & provenance

WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.

2structured study records
1outcome records
5linked source records

How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.

Show supporting and discovery sources

Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.